Charting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes

Front Pharmacol. 2024 Nov 26:15:1494492. doi: 10.3389/fphar.2024.1494492. eCollection 2024.

Abstract

The therapeutic potential of medical cannabis has garnered significant attention in recent years, prompting an urgent need for a comprehensive understanding of its effectiveness across various health outcomes. This article presents an Evidence Map that systematically summarizes clinical evidence on the use of medical cannabis, including the health conditions it addresses, the interventions employed, and the resulting clinical outcomes. The objective is to map the effectiveness of medical cannabis in relation to a wide range of health outcomes. The systematic review process involved two independent, blinded literature researchers who screened the search output using Rayyan software. For studies deemed relevant, full texts were obtained to clarify inclusion or exclusion criteria, and any disagreements were resolved through group discussion. Out of 1,840 initial references, 279 potential studies were selected and read in full, resulting in the inclusion of 194 studies in this evidence map. The results highlight the use of various cannabis formulations, including those based on isolated cannabidiol (CBD). Seventy-one distinct health outcomes were identified in the systematic reviews, with the most reported outcomes being related to various types of pain and patient safety. Other frequently studied outcomes included appetite regulation, chemotherapy-induced nausea and vomiting, and muscle spasticity. Notably, 278 out of 489 descriptions of treatment effects for these health outcomes reported either "Positive" or "Potentially Positive" effects. When considering only high-quality systematic reviews, as evaluated by the AMSTAR 2 tool, 42 out of 67 descriptions of treatment effects for up to 20 health outcomes were classified as "Positive" or "Potentially Positive." These outcomes included pain, insomnia, seizures, anxiety, muscle spasticity, multiple sclerosis, urinary incontinence, anorexia, and patient safety. This evidence map provides a comprehensive overview of the current clinical evidence on medical cannabis, highlighting its potential therapeutic benefits across a range of health conditions and emphasizing the need for further high-quality research.

Keywords: CBD; cannabis products; complementary therapies; evidence map; integrative medicine; medical cannabis; public health.

Publication types

  • Review

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study is part of a project funded by the WeCann Academy in partnership with the Latin American and Caribbean Center on Health Sciences Information (BIREME - PAHO - WHO) and the Brazilian Academic Consortium for Integrative Health (CABSIN) to develop complementary therapies Evidence Gap Maps. The WeCann Academy funded the project, BIREME-librarians and CABSIN-research partners conducted the study; collection; management; analysis; interpretation of the data; preparation, review, and decision to submit the manuscript for publication. The findings and conclusions in this publication are those of the authors who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the WeCann Academy, BIREME-PAHO-WHO and CABSIN.